, Tracking Stock Market Picks
Enter Symbol:
Rating: AMRI
Overweight $25

Albany Molecular Research, Inc. (NASDAQ: AMRI) rated to Overweight with price target $25 by First Analysis Sec

Monday,  Oct 26, 2015  8:25 AM ET by Lynn Gilbert

First Analysis Sec rated Albany
Molecular Research, Inc. (NASDAQ: AMRI) to Overweight with price target $25.

Albany Molecular Research, Inc., provides scientific services, technologies and products. The Company's core business consists of a fee-for-service contract services platform encompassing drug discovery, development and manufacturing, and a separate, stand-alone research and development division consisting of technology investments, internal drug discovery and niche generic active pharmaceutical ingredient product development. With locations in the United States, Europe and Asia, the Company provides customers with a range of services and cost models. In January 2008, the Company completed the acquisition of FineKem Laboratories Pvt. Limited (FineKem), a manufacturing facility in Aurangabad, India.

First Analysis clients and partners can access the First Analysis research library on-line by clicking on the “Search research” link or entering a ticker (in the search box below) and hitting the return key. First Analysis Securities Corporation provides institutional investors with research on more than 100 publicly traded companies in its sectors of specialization. Our approach—a research focus that encompasses both private and public companies—leads to broad, deep understanding of our industries and companies. First Analysis is committed to long-term, life-cycle industry coverage. First Analysis Securities Corp. (FASC) is a registered broker/dealer with the FINRA and SIPC.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy